Keyword: Gilead Sciences

The cost of new cancer drug rollouts—$200,000 on average last year—is helping drive treatment costs toward $100 billion annually in the U.S. alone.

After pharma suffered an unexpected loss in this year's budget deal, the industry sees an opportunity to get some relief.

Gilead has opened its new $11 million manufacturing facility control lab in Ireland.

Gilead will locate the European manufacturing site for its CAR-T therapy Yescarta at a Netherlands airport to ensure quick turnaround for its patients.

Patients allege that Gilead held off on developing its better HIV candidates until older drugs neared the end of their patent lives.

Gilead may have some exciting prospects ahead, but for now, its cash-cow hepatitis C business is a big drag. The good news? It's a 'trough year.'

If the competition between Novartis and Gilead in relapsed large B-cell lymphoma comes down to price, it will be a close race.

Regeneron and Sanofi have an exclusive PCSK9 deal with Express Scripts, but one analyst believes it's a negative for the companies.

A Merck attorney who provided false testimony tainted the company's case, an appeals court ruled, and cost the company $200 million.